Catalyst Pharmaceuticals, Inc.
CPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $148,392 | $146,563 | $141,421 | $141,820 |
| % Growth | 1.2% | 3.6% | -0.3% | – |
| Cost of Goods Sold | $25,311 | $29,958 | $17,911 | $21,643 |
| Gross Profit | $123,081 | $116,605 | $123,510 | $120,177 |
| % Margin | 82.9% | 79.6% | 87.3% | 84.7% |
| R&D Expenses | $2,657 | $4,358 | $3,887 | $3,798 |
| G&A Expenses | $44,570 | $42,249 | $44,311 | $13,521 |
| SG&A Expenses | $47,470 | $45,949 | $46,911 | $44,192 |
| Sales & Mktg Exp. | $2,900 | $3,700 | $2,600 | $30,671 |
| Other Operating Expenses | $6,687 | $0 | $9,345 | $9,344 |
| Operating Expenses | $56,814 | $50,307 | $60,143 | $57,334 |
| Operating Income | $66,267 | $66,298 | $63,367 | $62,843 |
| % Margin | 44.7% | 45.2% | 44.8% | 44.3% |
| Other Income/Exp. Net | $4,768 | $2,995 | $7,919 | $11,338 |
| Pre-Tax Income | $71,035 | $69,293 | $71,286 | $74,181 |
| Tax Expense | $18,252 | $17,185 | $14,549 | $18,245 |
| Net Income | $52,783 | $52,108 | $56,737 | $55,936 |
| % Margin | 35.6% | 35.6% | 40.1% | 39.4% |
| EPS | 0.43 | 0.43 | 0.47 | 0.47 |
| % Growth | 0% | -8.5% | 0% | – |
| EPS Diluted | 0.42 | 0.41 | 0.45 | 0.44 |
| Weighted Avg Shares Out | 122,601 | 122,163 | 121,472 | 119,892 |
| Weighted Avg Shares Out Dil | 127,090 | 127,543 | 126,958 | 126,280 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $5,947 | $5,275 | $4,616 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $9,416 | $9,460 | $9,460 | $9,458 |
| EBITDA | $80,451 | $78,753 | $72,827 | $72,301 |
| % Margin | 54.2% | 53.7% | 51.5% | 51% |